On the other hand, patients with HER2+ breast cancer and worse prognosis may have a poor response to trastuzumab therapy do to an ineffective Th1-mediated immune response and accordingly a reduced NK-mediated tumor cell lysis resulting in reduced levels of serum miR-19a. This evidence concerns the gene ERBB2 and neoplasm.